Becton, Dickinson and Company

565 articles with Becton, Dickinson and Company

• Thermo Fisher Scientific to Acquire Advanced Bioprocessing Business from BD

  9/7/2018

  Thermo Fisher Scientific Inc. has signed a definitive agreement with BD (Becton, Dickinson and Company)

• BD Statement on Divestiture of Advanced Bioprocessing Business

  9/7/2018

  BD (Becton, Dickinson and Company) (NYSE: BDX) today issued the following statement regarding the sale of its Advanced Bioprocessing business to Thermo Fisher Scientific

• BD to Present at the Morgan Stanley 2018 Global Healthcare Conference

  8/30/2018

  BD (Becton, Dickinson and Company) announced today that it will present at the Morgan Stanley 2018 Global Healthcare Conference on Wednesday, September 12, 2018, at 11:40 a.m. ET.

• BD Awards $1 Million in Grants to Help Community Health Centers Drive Effective Medication Use Among Vulnerable Patients

  8/28/2018

  BD (Becton, Dickinson and Company), Direct Relief, and the National Association of Community Health Centers (NACHC) recently awarded five community health centers with a total of $1 million in grant funding, which will be used to expand programs that help vulnerable patients more effectively manage their medications.

• BD to Present at the Wells Fargo Securities 2018 Healthcare Conference

  8/22/2018

  BD (Becton, Dickinson and Company) announced today that it will present at the Wells Fargo Securities 2018 Healthcare Conference on Wednesday, September 5, 2018, at 3:00 PM ET.

• BD Elects Jeffrey Henderson to Board of Directors

  8/16/2018

  Henderson, 53, is the non-executive chairman of the board of Qualcomm, Inc. and serves on the board of directors at FibroGen, Inc. and Halozyme Therapeutics, Inc. as well as serving as an advisory director to Berkshire Partners LLC.

• BD Announces Results For 2018 Third Fiscal Quarter; Raises Fiscal 2018 Revenue Guidance

  8/2/2018

  As reported, revenues of $4.278 billion increased 41.0 percent.

• BD Appoints Simon Campion to Interventional Segment President

  8/1/2018

  BD (Becton, Dickinson and Company) appointed Simon Campion as executive vice president of BD and president, BD Interventional segment, effective Sept. 4.

• BD Drives the Future of Immunology Research with Expanded Offerings for Simultaneous RNA and Protein Expression Analysis

  7/26/2018

  BD® AbSeq Assay Enables Deeper Understanding of Role Individual Cells Play in the Immune System

• BD Board Declares Dividends of $0.75 Per Common Share

  7/24/2018

  The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.75 per common share, payable on September 28, 2018 to holders of record on September 7, 2018.

• BD Shares Progress towards Achieving 2020 Sustainability Goals

  7/12/2018

  BD (Becton, Dickinson and Company)  issued its 2017 Sustainability Performance Update that focuses on four key strategic areas that support the company's 2020 Sustainability Goals.

• BD Acquires TVA Medical to Advance Leadership in Solutions for Chronic Kidney Disease

  7/9/2018

  everlinQ™ endoAVF System Receives FDA De Novo Marketing Authorization

• BD Announces Live Webcast Of Third Fiscal Quarter Earnings Conference Call

  7/5/2018

  BD (Becton, Dickinson and Company) announced today that it will conduct a live webcast of its third fiscal quarter 2018 earnings conference call on Thursday, August 2, 2018, at 8:00 a.m. (ET).

• 

  A Look at the Top 10 Medical Device Companies in 2018

  6/12/2018

  The medical device market was about $521.2 billion last year and is projected to hit $674.5 billion by 2022. Here’s a look at the top 10 medical device companies in the world this year.

• BD, Helmer Scientific Collaborate to Introduce First Fully Integrated Refrigerated Automated Dispensing Solution

  6/4/2018

  BD (Becton, Dickinson and Company) and Helmer Scientific announced a collaboration to introduce an industry-first, medical-grade refrigerated solution integrated with an automated dispensing system to provide clinicians secure, single line-item access to high-risk and high-value refrigerated medications.

• BD to Present at Investor Healthcare Conferences

  6/1/2018

  BD (Becton, Dickinson and Company) announced that it will present at the several upcoming investor healthcare conferences.

• BD Names John DeFord Chief Technology Officer

  6/1/2018

  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today appointed John A. DeFord as executive vice president and chief technology officer.

• BD Announces Results For 2018 Second Fiscal Quarter; Raises Fiscal 2018 Guidance

  5/3/2018

  BD (Becton, Dickinson and Company) reported quarterly revenues of $4.222 billion for the second fiscal quarter ended March 31, 2018.

• BD Launches BD FACSymphony™ High-Speed Cell Analyzer to Enable Identification and Analysis of Rare Cell Types

  4/29/2018

  BD (Becton, Dickinson and Company) announced the launch of the BD FACSymphony™ system, a novel cell analyzer enabling the simultaneous measurement of up to 50 different characteristics of a single cell.

• BD Names Three Executives to Segment Leadership Roles

  4/27/2018

  BD announced three executive appointments to the positions of segment president.